


# VTE risk varies by hormone therapy formulation

September 18 2012

---



The risk of venous thromboembolism in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest risk seen in users of oral estrogen-progestin HT containing medroxyprogesterone acetate, according to research published online Sept. 10 in the *Journal of Thrombosis and Haemostasis*.

(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin HT containing medroxyprogesterone acetate, according to research published online Sept. 10 in the *Journal of Thrombosis and Haemostasis*.

Siân Sweetland, M.D., of the University of Oxford in the United Kingdom, and colleagues conducted a study using [National Health Service](#) data from 1,058,259 [postmenopausal women](#) to evaluate the association of VTE with HT use.

The researchers found that the risk of VTE in women using oral estrogen-progestin and oral estrogen-only HT was 2.07- and 1.42-fold higher, respectively, than for women who had never used HT. The risk of VTE was highest for formulations containing [medroxyprogesterone](#) acetate. Similar results were observed for [deep vein thrombosis](#), with or without pulmonary embolism. The overall odds of experiencing a VTE event ranged from one in 250 for estrogen-progestin with medroxyprogesterone acetate, one in 390 for estrogen-progestin HT containing norethisterone/norgestrel, one in 475 for oral estrogen-only HT, to one in 660 postmenopausal women who had never used HT.

"Both route of administration and the specific constituents of HT have a significant impact on the risk of VTE in middle-aged women," the authors write. "The risk of VTE was highest for current users of oral combined estrogen-progestin HT at the time of last contact and in particular for users of estrogen-progestin preparations containing medroxyprogesterone [acetate](#). Risk was lower but significantly increased in users of oral estrogen-only HT, but there was no increased risk for current users of transdermal estrogen HT."

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2012 [HealthDay](#). All rights reserved.

Citation: VTE risk varies by hormone therapy formulation (2012, September 18) retrieved 26 April 2024 from <https://medicalxpress.com/news/2012-09-vte-varies-hormone-therapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
---